10-Q: FitLife Brands Q3 Revenue Soars 47% on Irwin Acquisition

FitLife Brands reports a significant 47% revenue increase in Q3 2025 driven by the Irwin Naturals acquisition, despite a 57% drop in net income.

Summary

• Revenue for the three months ended September 30, 2025, increased by 47% to $23,485 thousand, up from $15,977 thousand in the prior year.
• Net income for the three months ended September 30, 2025, decreased by 57% to $921 thousand, compared to $2,126 thousand in the same period last year.
• Diluted net income per share for Q3 2025 was $0.09, down from $0.21 in Q3 2024.
• The acquisition of Irwin Naturals on August 8, 2025, for approximately $42,500 thousand, was a primary driver of revenue growth.
• Irwin Naturals contributed $6,821 thousand in revenue and $504 thousand in net income from August 9 through September 30, 2025.
• Gross margin decreased to 37.2% in Q3 2025 from 43.8% in Q3 2024, primarily due to the Irwin acquisition's lower historical gross margin and $392 thousand in inventory step-up amortization.
• Operating income declined by 27% to $2,318 thousand in Q3 2025, largely due to increased merger and acquisition related expenses of $820 thousand.
• For the nine months ended September 30, 2025, revenue increased 12% to $55,548 thousand, while net income decreased 32% to $4,686 thousand.
• Adjusted EBITDA for Q3 2025 increased by 5.7% to $3,792 thousand, but for the nine months, it decreased by 4.8% to $10,535 thousand.
• Legacy FitLife brands saw a 5% revenue decrease in Q3 2025, with online revenue down 8% and wholesale revenue up 4%.
• MusclePharm revenue increased 55% in Q3 2025, driven by a 112% increase in wholesale revenue, but its gross margin fell to 19.8% due to promotional investments.
• Working capital decreased to $4,375 thousand as of September 30, 2025, from $6,832 thousand at December 31, 2024, mainly due to higher current debt balances.

Sentiment

Score: 4

Explanation: While revenue growth is strong due to the acquisition, the significant decline in net income, gross margin, and operating income, coupled with increased debt and a decrease in working capital, indicates immediate profitability challenges and integration costs. The performance of legacy brands is also a concern. The long-term benefits of the acquisition are yet to be realized, making the short-term outlook cautious.

Positives

• Total revenue increased significantly by 47% for the three months ended September 30, 2025, primarily due to the strategic acquisition of Irwin Naturals.
• MusclePharm brand revenue grew by 55% in Q3 2025, with wholesale revenue more than doubling, indicating successful market penetration efforts for this brand.
• The company successfully secured a new $40,625 thousand term loan and a $10,000 thousand revolving line of credit to fund the Irwin acquisition and refinance existing debt.
• Adjusted EBITDA for the three months ended September 30, 2025, increased by 5.7% to $3,792 thousand, demonstrating underlying operational strength when excluding non-recurring items.

Negatives

• Net income for the three months ended September 30, 2025, decreased substantially by 57% to $921 thousand, indicating a significant impact on profitability despite revenue growth.
• Gross margin declined to 37.2% in Q3 2025 from 43.8% in Q3 2024, primarily due to the lower gross margin profile of the acquired Irwin Naturals business and inventory step-up amortization.
• Operating income decreased by 27% in Q3 2025, largely due to a substantial increase in merger and acquisition related expenses ($820 thousand vs. $59 thousand in Q3 2024).
• Legacy FitLife brands experienced a 5% revenue decrease in Q3 2025, with online revenue declining by 8%, suggesting challenges in core brand performance.
• MusclePharm's gross margin significantly decreased to 19.8% from 35.5% in the prior year, indicating that revenue growth is coming at the cost of profitability due to promotional investments.
• Working capital decreased from $6,832 thousand at December 31, 2024, to $4,375 thousand at September 30, 2025, reflecting increased current debt obligations.

Risks

• The company is in the process of determining the fair value of Irwin's intangible assets and the appropriate accounting for the acquisition, which could lead to future adjustments to financial statements.
• Significant estimates and assumptions are required for financial reporting, particularly for reserves, allowances, purchase price allocation, goodwill impairment, and deferred tax assets, and actual results may differ.
• The company's stock price fluctuations could impact the fair value of the reporting unit, potentially leading to goodwill impairment in future periods.
• Customer concentration risk exists with GNC, which accounted for 13% of net sales in Q3 2025 and 17% for the nine months ended September 30, 2025.
• Exposure to fluctuations in foreign currencies due to the MRC acquisition in 2023, although no foreign currency hedging transactions were entered into during the period.
• Interest rate risk related to variable-rate borrowings under the Credit Agreement, although approximately 50% of the term loan is hedged with an interest rate swap.

Future Outlook

The company anticipates that cash derived from operations and existing cash reserves, along with available borrowings under the Line of Credit, will be sufficient to provide for liquidity for the next twelve months. Management expects to achieve anticipated operating efficiencies as a result of the Irwin acquisition, which are not yet reflected in pro forma financial information. Promotional efforts for the MusclePharm brand are expected to continue for the foreseeable future, potentially causing fluctuations in gross margin and contribution margin.

Management Comments

• Management believes that contribution, defined as gross profit less advertising and marketing expenditures, is a particularly relevant performance metric as it incorporates gross profit and associated advertising/marketing expense for specific brands.
• Management intends to provide detailed disclosure for acquired brands for approximately two years post-transaction, after which performance will be reported as part of Legacy FitLife results.
• Management determined there were no indicators of goodwill impairment at September 30, 2025, and will perform its next impairment analysis in December 2025.

Industry Context

The nutritional supplements and wellness products industry continues to see consolidation and strategic acquisitions, as evidenced by FitLife Brands' acquisition of Irwin Naturals. The shift in revenue mix towards wholesale channels (56% in Q3 2025 vs. 32% in Q3 2024) reflects the integration of Irwin Naturals, which primarily operates through wholesale. The company's continued investment in promotional activities for brands like MusclePharm suggests a competitive market where market share gains may require significant marketing spend, potentially impacting margins. The decline in online revenue for Legacy FitLife, particularly Dr. Tobias on Amazon, highlights the dynamic nature of e-commerce platforms and the need for continuous adaptation in digital marketing strategies.

Comparison to Industry Standards

• The acquisition of Irwin Naturals, a well-known brand in the mass market and health food store segments, aligns with industry trends of companies expanding their product portfolios and distribution channels to capture a broader consumer base.
• The decline in gross margin post-acquisition (37.2% for FitLife consolidated vs. Irwin's historical lower gross margin) is a common outcome when integrating businesses with different profitability profiles, similar to other roll-up strategies in the consumer goods sector.
• Increased promotional spending for MusclePharm, leading to a lower gross margin (19.8%), is a strategy often employed by companies in competitive segments to gain or defend market share, comparable to tactics seen in the broader sports nutrition market.
• The decrease in online revenue for Legacy FitLife brands, particularly on Amazon, reflects challenges faced by many brands in maintaining visibility and traffic on large e-commerce platforms amidst intense competition and evolving algorithms, a common industry hurdle.

Legal Proceedings

• The company is not currently involved in any litigation that is believed to have a material adverse effect on its financial condition or results of operations.

Stakeholder Impact

• Shareholders may experience short-term pressure on earnings per share due to the decline in net income and increased share count from stock option exercises, despite revenue growth.
• Creditors will see increased debt levels due to the new term loan and revolving line of credit, secured by substantially all company assets, but also new financial covenants designed to manage leverage and coverage.
• Employees of Irwin Naturals are now integrated into FitLife Brands, potentially leading to operational synergies and changes in corporate culture.
• Customers of Irwin Naturals will continue to access products through wholesale channels, while FitLife's existing customer base may see expanded product offerings.

Next Steps

• Finalize the fair value determination of Irwin Naturals' tangible and intangible assets and the appropriate accounting for the acquisition within the one-year measurement period.
• Make quarterly principal payments on the Irwin Term Loan, commencing December 31, 2025.
• Maintain financial covenants, including a Senior Funded Debt to EBITDA Ratio and a Fixed Charge Coverage Ratio, starting with the fiscal quarter ending December 31, 2025.
• Perform the next goodwill impairment analysis in December 2025.
• Continue evaluating the provisions of ASU 2024-03 and assessing its potential impact on financial statement disclosures.

Key Dates

Recommendation

The company's significant revenue growth driven by the Irwin Naturals acquisition is a positive strategic move, expanding its market presence and product portfolio. However, this growth comes at a substantial cost, evidenced by the sharp decline in net income, gross margin, and operating income, along with increased debt. The integration of Irwin Naturals and the promotional investments in MusclePharm are expected to impact profitability in the short term. A 'hold' recommendation allows investors to observe the successful integration of the acquired assets, the realization of anticipated synergies, and whether the promotional efforts translate into sustainable, profitable growth without further eroding margins. The increased leverage and immediate dilution of profitability warrant caution, but the long-term potential from strategic expansion prevents a 'sell' recommendation at this stage.

Keywords

Nutritional Supplements, Wellness Products, Irwin Naturals Acquisition, Q3 2025 Earnings, FitLife Brands, FTLF, SEC 10-Q, Business Combination, Gross Margin, Net Income, EBITDA, Debt Financing, MusclePharm, Legacy FitLife, GNC Sales